



## CIO EMEA outlook 2021: knowns and unknowns after a tumultuous year

William Davies, CIO, EMEA

- We see three themes dominating 2021: the development of a Covid-19 vaccine; the political make-up of the US following the November election; and Brexit.
- Our research intensity powers our understanding of these themes, trends and events, and positions us strongly to navigate through financial markets for our clients.
- Following unprecedented levels of stimulus the level of debt is going to be even greater than it was after 2009 and we will emerge into a world of low inflation, low growth and low interest rates – not a backdrop where economic sensitivity is likely to outperform over the longer term.
- Instead, this environment will favour the type of investments that Columbia Threadneedle Investments makes – long-duration assets and durable growth companies with: sustainable returns driven by a sizeable moat, a high Porter’s Five Forces score, strong environmental, social and governance credentials and sustainable competitive advantage. We want risk within portfolios, but we want controlled risk.
- The UK equity market is clearly cheaper than others and may benefit if we see the recovery we expect to see over the next 9-12 months; Europe and Japan are in a similar position. Longer term, we can see further potential in the US and Asia/emerging markets.
- We like an element of risk within credit, but we believe investment grade is ultimately a better home for it than high yield, where we see a greater risk from higher financial leverage, particularly when coupled with high operational leverage.
- As active managers we have performed strongly throughout the pandemic crisis, using our knowledge, expertise, collaborative skills and research capabilities to remain calm. This consistent approach will continue to be followed in 2021, helping us identify trends and investment opportunities, whatever next year may bring.





## Introduction

At the beginning of the year we were threatened with excitement, be that trade wars or ongoing political upheaval in the Europe and the US. None of us were prepared for a global pandemic. In March, markets descended into chaos as Covid-19 swept around the world, with equity markets down by more than 30% and credit spreads widening hugely. From there we have witnessed an initial rally driven by central bank stimulus, followed by ongoing market volatility and more recently a “sugar rush” of market excitement following the announcement of potentially effective vaccines.

All of this played out against a backdrop of three areas that will continue to be of huge importance in 2021: the development of further effective Covid-19 vaccines; the political make-up of the US following the November election and the forthcoming runoff elections that will decide which party controls the Senate; and Brexit.

As asset managers we are only able to navigate our way through the potential scenarios and impacts from the above factors because of our research capabilities, what we call our Research Intensity. These power our understanding of themes, trends and events, lead us to attractive investment opportunities and allow us to maintain an element of calm in the midst of “panic”.

### Covid-19: the search for a mass vaccine nears its end

When the coronavirus first hit, our research work was focused on its potential spread, because that had impacts at a corporate level as well as a personal one – from travel and healthcare to banks and retail. While the data we had available was limited to the number of tests, hospitalisations and deaths, our research teams focused on diagnostics, treatment and vaccine development. Looking forward it is important to focus on when successful vaccines will be available, how effective they may be and who will receive them.

It is all about knowns versus unknowns. For example, we know numerous vaccines are expected in 2021, with at least 30 expected to publish results throughout the year, but we don't know how many will be approved

and when during the year. We know three have already been announced with 90%-plus efficacy rates (impressive given that vaccines are usually approved if they have 50% efficacy), but we do not yet know the full differences between these vaccines. We know there will be a rapid uptake from the general public, but we do not know the extent to which there will be hesitancy from certain sub-groups.

We know that while the end of the pandemic is coming, the fundamentals are likely to deteriorate first because many economies are still shutting down – it is getting worse before it gets better.

But markets have begun to look through the short term to the sunny upside of the vaccine-led recovery. Where previously they appeared





vulnerable to any spike in positive tests or hospitalisations, now they appear more sanguine.

But what will that recovery look like? It will be based on the speed with which vaccines are rolled out, the numbers of people receiving them, and how quickly people return to “normal” activities. In April 2020 our original forecast was that the recovery would be U-shaped and we would see a level of economic activity back at pre-pandemic levels by the end of 2022. However, the strong efficacy of the drugs from Moderna et al would encourage us to believe that the recovery from the pandemic may be quicker in 2021 than we had previously anticipated.




**The critical thing for us is to ensure we remain invested in the companies that are going to make it through and ultimately benefit from the economy reopening.**

That should bring forward economic recovery by as much as nine months, meaning we see a recovery to pre-pandemic levels by early-2022 or possibly even the end of 2021. The critical thing for us is to ensure we remain invested in the companies that are going to make it through and ultimately benefit from the economy reopening.

Since the pandemic and lockdowns we have seen consumers become more comfortable buying things online that they had traditionally resisted, such as clothing and footwear. As a result, the trend towards e-commerce has been pulled forward. If you add to this the build-up of personal savings caused by people being unable to spend as much as they used to, you have a potential explosion of pent-up demand to come in 2021 (Figure 1). In our view, the greatest growth in spending will more likely be on “experiences” hit during the pandemic (for example, leisure and travel) rather than “things” (washing machines and cars), which was a consumer trend we had been witnessing for some years already.

**Figure 1: US savings rocket during the pandemic**



Source: Hutchins Center calculations from Bureau of Economic Analysis data, as at November 2020.

That said, there is a subtlety to the recovery that we must heed. It could be a mistake to believe people will begin flying to places and staying in hotels at the same rate as before. With the digitisation of the economy and the use of video conferencing, for example, there is a strong case that business travel and spending will not return to pre-pandemic levels. As a result, certain hotel groups and airlines that are geared towards business may not do as well as more leisure-focused airlines as we emerge from our Covid hibernation.

**US political landscape: healthy for equities and credit?**

Joe Biden’s victory in November, coupled with the result of the run-off election in Georgia, has seen the Democrats gain the presidency as well as marginal control of the Senate and the House of Representatives.





However, given the make-up of the House and Senate – and the razor-thin voting majority in the Senate – it will not be easy for Biden to implement radical change.

That said, he appears to be a more stable, consistent leader and we anticipate he will more likely heal domestic divisions as well as repair international relationships. He has talked about rejoining the Paris Accord, for example, and this will have a positive impact on slowing climate change and aligning the US with other nations. We also expect him to continue taking a tough line on China, but with a different style to the rhetoric of the past few years and a more consistent approach. Biden will no doubt have a more constructive relationship with Europe too, and Germany and France in particular, which has deteriorated in the past four years.

A new round of stimulus will no doubt be the first order of business for the Biden presidency, likely containing a combination of small business support and another round of direct payments to households. We expect changes in health care, though the future in this sector is difficult to predict, and we believe the climate will be addressed in the early months: extending current schemes (and creating new ones) that incentivise clean energy is likely.

But given that the Democrat's Senate "majority" is so slim, we will probably find ourselves in something of a middle ground, which is a reasonably healthy position for equity and credit markets. Medium term it is certainly one that benefits the likes of US utilities, consumer staples and tech, but which may have negative implications for financials, energy and health care (although financials and energy are likely beneficiaries from the recovery/vaccines, albeit not as much as if stimulus were greater).

## Brexit

We now have a Brexit deal but there remain elements of the agreement that include decisions still to be agreed. Going forward, it will be important for the UK prime minister to build a relationship with Biden in the US, just as it is also crucial that Biden builds a strong relationship with the EU.



*The UK has endured an extremely challenging period... any positive news – be that vaccine-related, Brexit or otherwise – could open the door for a stronger performance from UK equities in 2021.*

This leads me to the UK equity market, for which 2021 is hugely important. The UK has endured an extremely challenging period, buffeted by ongoing Brexit uncertainty, political upheaval and the pandemic. Companies in the UK appear cheap, which is evident in the rising number of takeovers and mergers and acquisitions. With that in mind, I believe any positive news – be that vaccine-related, Brexit or otherwise – could open the door for a stronger performance from UK equities in 2021.

## Markets, themes and opportunities: quality set to endure

At the end of the global financial crisis in 2009 we saw a sugar rush within markets, specifically for a couple of quarters from March that year where economy-sensitive stocks performed very well. This is being mimicked somewhat today, but following unprecedented levels of stimulus and government intervention the level of debt is going to be even greater than it was after 2009, so that rush of recovery is unlikely to persist. We will thus emerge into a world of low inflation, low growth and low interest rates – a repeat of the 2010s in some way. Such a backdrop is not one where traditional value is likely to outperform over the longer term.





A big fiscal deficit is of course potentially inflationary, but any inflation is unlikely to persist for two reasons: one is that there is a lot of spare capacity within the economy, as measured by unemployment and low industrial capacity utilisation; and secondly, any inflation will be accompanied by rising interest rates which will quickly dampen growth due to the cost of servicing such high levels of debt.

We would therefore caution against a rush to value and poorly performing stocks irrespective of the outlook, and would also caution investors about value traps.

Instead, we expect this environment will favour the type of investments that Columbia Threadneedle Investments makes – long-duration assets and durable growth companies that keep grinding higher because they have all the characteristics we look for in a business: sustainable returns driven by a sizeable moat; a high Porter's Five Forces score; strong environmental, social and governance credentials; and sustainable competitive advantage. We want risk within portfolios, but we want controlled risk.



*Volatility will likely continue to be elevated in 2021, but it would be a mistake to make knee-jerk reactions to sudden strong moves in markets. Again, as investors we must maintain our strategic positions and focus on the longer term.*

Volatility will likely continue to be elevated in 2021, but it would be a mistake to make knee-jerk reactions to sudden strong moves in markets. Again, as investors we must maintain our strategic positions and focus on the longer term.

## Equities

Investors must be prepared for current secular trends such as digitisation and automation to continue, while the growth of e-commerce has been pulled forward by the pandemic. The stocks benefiting from these trends continued to outperform in 2020 and we expect them to do so in the future. We also expect cyclical areas that were hit by Covid-19 to bounce back when the recovery kicks in, including travel and entertainment. That said, investors should not ignore the companies which might have underperformed during the pandemic but have the financial strength and the business models to gain market share on the other side.

Looking at specific regions, it is a question of short term versus long term. The **UK** is clearly cheaper than other markets around the world and may benefit if we see the expected recovery over the next nine to 12 months; and I would put **Europe** in that camp too. Longer term we can see potential in the US and Asia/emerging markets.

In **the US** we see a market which is broader than other markets around the world and in the case of the technology sector is a leader in terms of digitalisation around the world, but we see its recovery taking longer.

As ever with **emerging markets** there are those countries where we see growth ahead, and others where we see challenges, such as Brazil or India (although they are a smaller part of the emerging market investment landscape). The largest emerging market is of course China, which is growing this year and was the first to emerge economically from Covid-19. Other countries are at different stages of their recovery and this will be linked to how quickly mass vaccinations are rolled out, but we see China at the forefront and the likes of India and Latin America further behind.





In **Japan** we would look at Shinzo Abe's replacement as prime minister, Yoshihide Suga, as being very much the continuity candidate. He has made positive noises about continuing on the path that has seen the country embrace corporate governance and regulatory reform, digital transformation and a more attractive environment for foreign tourists and workers. Japan has significant exposure to industry within its market, particularly to Chinese investment, so we see an improved outlook for Japanese equities going into the recovery, even if Japan's demographics do continue to create a real headwind.

### Credit

Investment grade markets benefited directly from fiscal stimulus such as corporate bond-buying programmes and furlough schemes. We do see some downgrade risk when those props are removed, but there is a greater risk in the high yield area where investors must tread carefully due to higher financial leverage. Not all those companies are going to make it through – indeed, if high financial leverage is linked to operational leverage, which it often is, one should tread ever so carefully. So while we like an element of risk within credit, we believe investment grade is ultimately a better home for it than high yield.

### Active managers powered by research

Our research teams work collaboratively across all major asset classes, using big data and analytics such as machine learning and augmented intelligence to turn information into forward-looking insights that add real value to investment decisions, enabling consistent and replicable outcomes for our clients. Research intensity is at the heart of our investment process.

This year we have focused our research on Covid-19 and its impact, including the health care impacts, economic and market impacts, and long-term implications. This has helped inform our view of how we see the trajectory of the virus, vaccine development and economic recovery. We call this inter-linking of our analysts and research team with our fund managers to create well-argued and sensible views the “path forward”. It has given us insights throughout the year that have allowed us to add value for our clients.



*As active managers we have performed strongly throughout the pandemic crisis, using our knowledge, expertise, collaborative skills and research capabilities to remain calm.*

As active managers we have performed strongly throughout the pandemic crisis, using our knowledge, expertise, collaborative skills and research capabilities to remain calm. Whatever 2021 brings, this approach, coupled with our experience of 2020, means we will be particularly well positioned to navigate through financial markets for our clients.



To find out more visit  
**columbiathreadneedle.com**



**Important Information:**

**For use by Professional and/or Qualified Investors only (not to be used with or passed on to retail clients).**

This document is intended for informational purposes only and should not be considered representative of any particular investment. This should not be considered an offer or solicitation to buy or sell any securities or other financial instruments, or to provide investment advice or services. **Investing involves risk including the risk of loss of principal. Your capital is at risk.** Market risk may affect a single issuer, sector of the economy, industry or the market as a whole. The value of investments is not guaranteed, and therefore an investor may not get back the amount invested. **International investing** involves certain risks and volatility due to potential political, economic or currency fluctuations and different financial and accounting standards. **The securities included herein are for illustrative purposes only, subject to change and should not be construed as a recommendation to buy or sell. Securities discussed may or may not prove profitable.** The views expressed are as of the date given, may change as market or other conditions change and may differ from views expressed by other Columbia Threadneedle Investments (Columbia Threadneedle) associates or affiliates. Actual investments or investment decisions made by Columbia Threadneedle and its affiliates, whether for its own account or on behalf of clients, may not necessarily reflect the views expressed. This information is not intended to provide investment advice and does not take into consideration individual investor circumstances. Investment decisions should always be made based on an investor's specific financial needs, objectives, goals, time horizon and risk tolerance. Asset classes described may not be suitable for all investors. **Past performance does not guarantee future results, and no forecast should be considered a guarantee either.** Information and opinions provided by third parties have been obtained from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. This document and its contents have not been reviewed by any regulatory authority.

**In Australia:** Issued by Threadneedle Investments Singapore (Pte.) Limited ["TIS"], ARBN 600 027 414. TIS is exempt from the requirement to hold an Australian financial services licence under the Corporations Act and relies on Class Order 03/1102 in marketing and providing financial services to Australian wholesale clients as defined in Section 761G of the Corporations Act 2001. TIS is regulated in Singapore (Registration number: 201101559W) by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289), which differ from Australian laws.

**In Singapore:** Issued by Threadneedle Investments Singapore (Pte.) Limited, 3 Killiney Road, #07-07, Winsland House 1, Singapore 239519, which is regulated in Singapore by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289). Registration number: 201101559W. This document has not been reviewed by the Monetary Authority of Singapore.

**In Hong Kong:** Issued by Threadneedle Portfolio Services Hong Kong Limited 天利投資管理香港有限公司. Unit 3004, Two Exchange Square, 8 Connaught Place, Hong Kong, which is licensed by the Securities and Futures Commission ("SFC") to conduct Type 1 regulated activities (CE:AQ4779). Registered in Hong Kong under the ce (Chapter 622), No. 1173058.

**In EMEA:** Issued by Threadneedle Asset Management Limited. Registered in England and Wales, Registered No. 573204, Cannon Place, 78 Cannon Street, London EC4N 6AG, United Kingdom. Authorised and regulated in the UK by the Financial Conduct Authority. This document is distributed by Columbia Threadneedle Investments (ME) Limited, which is regulated by the Dubai Financial Services Authority (DFSA). For Distributors: This document is intended to provide distributors' with information about Group products and services and is not for further distribution. For Institutional Clients: The information in this document is not intended as financial advice and is only intended for persons with appropriate investment knowledge and who meet the regulatory criteria to be classified as a Professional Client or Market Counterparties and no other Person should act upon it.

**Columbia Threadneedle Investments is the global brand name of the Columbia and Threadneedle group of companies. columbiathreadneedle.com**

Issued 12.20 | Valid to 06.21 | J31065 | 3327556